Congresses

This Congress is the final activity of a COIL (Collaborative Online International Learning) project. It will include plenary conferences, workshops and oral communications focusing on the main career prospects that Pharmacy, Biotechnology, Nutrition and Dietetics degrees offer. The oral communications have been prepared by the students from the organizing universities and are based on interviews with 75 experts from a range of professional sectors. These experts are from 11 countries and work in 64 Institutions.

Who can participate? It is aimed at anyone interested in the career opportunities worldwide in the Health Sector (students, recent graduates, and professionals).

Date: 3 July 2021 (Online on Zoom and Teams) from 8:30h until 16:30h (UK time); from 9:30h until 17:30h (Spanish time).

How to register: the registration is free, but we have limited places. Don’t miss this opportunity and register as soon as possible at:

REGISTER NOW

Registration deadline: 19 June.

Organising committee: Paola Otero Gómez¹, Carmen Pérez García¹, Carolina Hurtado Marcos¹, Francesca Spyrakis², Cinzia Margherita Bertea², Giulia Caron², Sonja Visentin², Robert Davies³, Palma Gharanei³, Maryam Babba³.

¹Universidad CEU San Pablo; Spain; ²Università degli study di Torino, Italy; ³Coventry University, UK.

• Pharma and Biotech Industry:
  • Regulatory Affairs
  • Corporate Affairs
  • Marketing
  • Medical Affairs
  • Product Development
  • Quality Assurance
  • Project Management
• Community Pharmacy
• Hospital Pharmacy
• Medicines Agencies
• Research
• Consulting
• Molecular Diagnostics
• Patents
• Primary Care
• Public Health Nutrition
• Food and Nutrition Communication
• Clinical Nutrition
• Food Industry
• Higher Education Teaching

• Argentina
• Italy
• Switzerland
• Belgium
• Netherlands
• UK
• Canada
• Portugal
• USA
• Israel
• Spain

• Prof. Luis Fernando Alguacil Merino
• Prof. Antonio Aguilar Ros
• Prof. Victoria Cano González
• Prof. Marta Gil Ortega
• Prof. Carmen González Martín
• Prof. Esther Gramage Caro
• Prof. Gonzalo Herradón Gil-Gallardo
• Prof. Beatriz Merino Palacios
• Prof. Lidia Morales Goyanes
• Prof. Nuria del Olmo Izquierdo
• Prof. Carmen Pérez García
• Prof. Fernanda Rey-Stolle Valcarce
• Prof. Mariano Ruiz Gayo
• Prof. Beatriz Somoza Hernández

9:00 Handing over of documentation and opening (Assembly Hall)

9:30 Oral communications

• Session I.A: Neurodegenerative diseases (Assembly Hall)

• Session I.B: Cardiovascular (Multi-purpose Room 1)
• Session I.C: New horizons in the study of addictions (Multi-purpose Room 2)
• Session I.D: Oxidative stress and cellular excitability (Classroom A 1.3.1)

11:15 Coffee break (EPS Cafeteria)

12:00 Oral communications

• Session II.A: Neurotoxicity and Neuroprotection I (Assembly hall)
• Session II.B: Inflammation and oxidative stress (Multi-purpose Room 1)
• Session II.C: Clinical Pharmacology I (Multi-purpose Room 2)

13:00 Plenary conference (Assembly hall)

• Technological innovation and interdisciplinary approach to the study of Alzheimer's disease. Javier DeFelipe (Instituto Cajal CSIC and Cortical Circuits Laboratory CTB, Universidad Politécnica de Madrid).

14:00 Lunch (Montepríncipe Campus Canteen)

15:30 Oral communications

• Session III.A: Neurotoxicity and Neuroprotection II (Assembly hall)
• Session III.B: Lipid metabolism and energy balance (Multi-purpose Room 1)
• Session III.C: Clinical Pharmacology II (Multi-purpose Room 2)

16:30 Coffe break (EPS Cafeteria)

17:00 Oral communications

• Session IV.A: Mitochondria and energy metabolism (Assembly hall)
• Session IV.B: Advances in anti-tumour therapeutics (Multi-purpose Room 1)
• Session IV.C: Vesicular recycling, exocytosis and synapsis (Multi-purpose Room 2)

18:00 Closing of the meeting

Awards to the best

• First award: ‘Regulación del ciclo vesicular sináptico por la dinámica del citoesqueleto de actina en neuronas granulares de cerebelo de rata’ presentado por Alberto Rampérez Martín.
• Second award: ‘ Modulación diferencial de los sistemas glutamatérgico, gabaérgico y endocannabinoide en el complejo basolateral de la amígdala en la incubación del craving de cocaína, heroína y sacarosa’ presentado por David Roura Martínez.

Important dates

Inscripciones y envío de resúmenes: 15 May – 15 June 2015
Congress date: 2 July 2015

Congress place

Montepríncipe Campus
Urbanización Montepríncipe
28925 Alcorcón Madrid, España
Telf. 91.372.47.00

• Beatriz de Pascual-Teresa (School of Pharmacy, Universidad CEU San Pablo, Madrid)
• Antoni Torrens (Partnerships in R&D and Strategic Alliances, Esteve, Barcelona)
• Ana Gradillas (School of Pharmacy, Universidad CEU San Pablo, Madrid)
• Ana Ramos (School of Pharmacy, Universidad CEU San Pablo, Madrid)
• Mª Fernanda Rey-Stolle (School of Pharmacy, Universidad CEU San Pablo, Madrid)
• Ana Castro (CSIC: Institute of Medical Chemistry, Madrid)
• Ana San Félix (CSIC: Institute of Medical Chemistry, Madrid)
• José María Zapico (School of Pharmacy, Universidad CEU San Pablo, Madrid)
•  

WEDNESDAY, 2 OCTOBER 

13:30 Registration

15:30 Opening Coral Barbas, Vicechancellor of Research, CEU-USP; Beatriz de Pascual-Teresa, Organizing Committee, CEU-USP; Antoni Torrens, President SEQT

Chairperson
Javier Rojo/Antoni Torrens

16:00 Inaugural Lecture: "Antibody-Based Therapeutics for Cancer Therapy"
Peter Senter, Seattle Genetics, EEUU

17:00 IS1: “Synthetic biology and smart therapeutic systems”
Guillermo de la Cueva Méndez (BIONAD- Centro Andaluz de Nanomedicina y Biotecnología, Málaga, Spain)

17:30 IS2: “Glycofullerenes for Biological Applications”
Nazario Martín León (Universidad Complutense de Madrid, Spain)

18:00 SEQT Awards

18:30 OC1: “A new strategy to gain selectivity within the gelatinases subfamily”
Benjamin Fabre. (Universidad CEU San Pablo, Madrid, Spain) Ramón Madroñero SEQT Award

20:00 Welcome Cocktail

THURSDAY, OCTOBER 3RD

MORNING SESSION

Chairperson:
Mª José Camarasa/Mª Luz López

09:00 IS3: “3D Pharmacophore Models: Efficient Tools for Hit Identification,Lead Optimization, and Ligand Profiling”
Thierry Langer (Prestwick Chemical, Illkirch, France)

09:30 IS4: “Integrating Intramolecular Hydrogen Bonding (IMHB) considerations in Drug Discovery using lipophilicity as a Tool”
Giulia Caron (University of Turin, Italy)

10:00 IS5: “Nucleic acids in G-quadruplex conformations as innovative targets against cancer”
Stefano Alcaro (Universitá "Magna Graecia", Catanzaro, Italy)

10:30 Coffee Break

11:00 IS6: “ORL-1 Antagonists: Lead Optimization and PET Tracer Development”
Angeles Martínez Grau (Lilly, S.A., Madrid, Spain)

11:30 IS7: “The asymmetric architecture of G protein-coupled receptor heteromers with G proteins explains signalling cross-talk”
Peter McCormick (Universidad de Barcelona)

12:00 Oral Communications
Communications (OC2-OC5)

OC2: “Synthesis and Pharmacological Evaluation of Acetaminophen Analogues with Antinociceptive Properties”
Pilar Goya (Instituto de Química Médica, CSIC, Madrid, Spain)

OC3: “Synthesis and Pharmacological Evaluation of Acetaminophen Analogues with Antinociceptive Properties”
Pilar Goya (Instituto de Química Médica, CSIC, Madrid, Spain)

OC3: “Applications of click chemistry in sphingolipid research”
Antonio Delgado (IQAC-CSIC, Barcelona, Spain)

OC4: “Computational chemistry for identifying differences among choline kinases active sites”
Lucía Serrán Aguilera (Universidad de Granada, Spain)

OC5: “Impact of fluorination on proteolytic stability of peptides: a case study using α-chymotrypsin and pepsin”
Jeremie Mortier (Free University of Berlin, Germany)

13:00 Lunch

AFTERNOON SESSION

Chairperson:
Pilar Goya/Julio Álvarez Builla

15:00 IS8: “Amino Acid-Derived β–Lactams: Synthesis, Biological Activity and Beyond”
Rosario González Muñiz (Instituto de Química Médica, CSIC, Madrid, Spain)

15:30 OC6: “New non-metathetic processes catalysed by ruthenium complexes for the synthesis of heterocycles”
Javier Pérez-Castells (Universidad CEU San Pablo, Madrid, Spain)

15:45: Poster Session and Coffee

16:45 Oral Communications (OC7-OC8)

OC7: “Merging of pineal neurochemicals. pharmacological profiles and neurogenic potential”
Mario de la Fuente Revenga (Instituto de Química Médica, CSIC, Madrid, Spain)

OC8: “Drugging the von hippel lindau E3 ubiquitin ligase: potential drugs and useful chemical tools”
Carles Galdeano (University of Dundee, Dundee, UK)

19:30 Cultural evening:
"Discover most unknown Madrid`s old town,even for locals; in a 1,30-1,45 hrs aprox walking tour seeing highlights bringing back its ancient past,legends,alleyways,monuments and curiosities with a fully licensed guides that will make you travel through the time" Underground: Puerta del Sol metro station.
 

FRIDAY, OCTOBER 4TH

MORNING SESSION

Chairperson
Jordi Gracia/Javier Fernández Gadea

09:00 IS9: “Next-Generation Inhibitors for Kinases, Histone-Deacetylases, and Histone Methyltransferases: The discovery of Slowness”
Gerhard Müller (Mercachem, The Netherlands)

09:30 IS10: “Exploring the kinome with kinase broad screening”
Gary Tresadern (Janssen R&D, Beerse, Belgium)

10:00 IS11: “Antibiotic Treatment of Tuberculosis: Old Problems, New Solutions”
Mónica Cacho Izquierdo (GlaxoSmithKline, Madrid, Spain)

10:30 Coffee Break

11:00 Oral Communications (OC9-OC12)

OC9: "Design of mycobacterium tuberculosis shikimate kinase inhibitors inspired by the enzymatic movements for catalytic turnover”
Verónica Prado (CIQUS, Universidad de Santiago de Compostela, Spain)

OC10: “From hit to lead in search of new inhibitors of the enzyme isoprenylcysteine carboxyl methyltransferase (ICMT)”
Silvia Ortega-Gutiérrez (Universidad Complutense, Madrid, Spain)

OC11: “Design, synthesis and biological evaluation of cyclic acylguanidines as bace-1 inhibitors: effect of ring size on activity and selectivity versus BACE-2”
Myriam Ciordia (Janssen Pharmaceutical Research & Development, Toledo, Spain)

OC12: “-Omics tools for studying changes in metabolic pathways of new drugs”
Isidre Masana (Agilent Technologies)

12:00 SEQT Meeting

13:00 Lunch

AFTERNOON SESSION

Chairperson
Concepción González Bello/Antonio Pineda

15:00 IS12: “ETP-CNIO Academic Early Drug Discovery: PIM Kinase Inhibitors”
Joaquín Pastor (CNIO- Centro Nacional de Investigaciones Oncológicas, Madrid, Spain)

15:30 OC13 “Different levels of apoptosis caused by enantiomers in breast cancer cells”
Joaquín M. Campos (Universidad de Granada, Spain)

15:45: Poster Session and Coffee

16:45 Oral Communications (OC14-OC16)

OC14: “Tumor vascular disrupting agents: identification and optimization of novel hits”
Mª Dolores Canela (Instituto de Química Médica, CSIC, Madrid, Spain)

OC15: “3-Substituted indole derivatives as antimitotic agents”
Raquel Álvarez Lozano (Universidad de Salamanca, Salamanca, Spain)

OC16: “Chemical biology for drug discovery: two case studies in drug repurposing”
Jordi Quintana (Parc Científic de Barcelona, Spain)

17:30 Concluding Remarks. Poster and Oral Communication Awards

21:00 Gala Dinner
Gala dinner will be held in "La Posada de la Villa”, a classic Spanish restaurant in Madrid. It is included in the distinguished Michelin Guide) and has been awarded in many occasions: Grand Collar Gourmet, the Chaîne des Rotisseurs, etc.

Posada de la Villa Restaurant C/ Cava Baja, 9. Underground: La Latina metro station. 

Important information about posters:

• Poster session 1: Thursday October 3rd 15:45-16:45: ODD numbers
• Poster session 1: Friday October 4th 15:45-16:45: EVEN numbers

• Antibody-Based Therapeutics for Cancer Therapy
  Dr. Peter SENTER
  (SEATTLE GENETICS, EEUU)
  
  Dr. Peter Senter. PhD in Chemistry from the University of Illinois followed by postdoctoral research at the Max-Planck Institute in Göttingen, Germany. He joined Seattle Genetics in 1998 and has served as Vice President, Chemistry since September 2002. Dr. Senter is responsible for research programs covering antibody-drug conjugates, anticancer prodrugs, and protein engineering. Before joining Seattle Genetics, he held positions at Cytokine Networks, Bristol Myers Squibb Pharmaceutical Research Institute, and the Dana Farber Cancer Institute. Dr. Senter is an Affiliate Professor in Bioengineering at the University of Washington and is the Senior Editor of Bioconjugate Chemistry, an ACS journal. He has authored more than 130 scientific publications and holds more than 40 patents
  
  

• Amino Acid-Derived β–Lactams: Synthesis, Biological Activity and Beyond
  Dr. Rosario GONZÁLEZ-MUÑIZ
  (IQM-CSIC, Madrid, Spain)

  Dr. Rosario González-Muñiz, Ph.D. in chemistry from Madrid Autónoma University, and post-doctoral stay at René Descartes University (Paris V). She is scientific researcher at the Medicinal Chemistry Institute (IQM-CSIC), where she was the Deputy Director (2005-2011). Specialist in peptides, peptidomimetics and bioactive small-molecules, her recent research interests include the design and synthesis of new modulators of protein-protein interactions and different types of ion channels.
  
  

• 3D Pharmacophore Models: Efficient Tools for Hit Identification,Lead Optimization, and Ligand Profiling
  Dr. Thierry LANGER
  (PRESTWICK CHEMICAL, Illkirch, France)

  Dr. Thierry Langer, CEO and President of Prestwick Chemical, is a well known scientist in the drug discovery field. Former Professor of pharmaceutical chemistry at Innsbruck University (Austria), and co-founder of the software company Inte:Ligand GmbH (Vienna, Austria), he is author of more than 160 original papers in the field of computational medicinal chemistry.
  
  

• Integrating Intramolecular Hydrogen Bonding (IMHB) considerations in Drug Discovery using lipophilicity as a Tool
  Dr. Giulia CARON
  (UNIVERSITY OF TURIN, Turin, Italy)

  Dr. Giulia Caron is assistant professor at University of Turin. She has a broad experience in the design, synthesis and phisycochemical characterization of biologically active molecules. Her recent research is focused on in silico techniques, applying QSAR and ADMET predictions in drug design and related areas. She is coauthor of more than 50 publications.

  More details at en.unito.it
  
  

• Nucleic acids in G-quadruplex conformations as innovative targets against cancer
  Dr. Stefano ALCARO
  (UNIVERSITÁ "MAGNA GRAECIA", Catanzaro, Italy)

  Stefano Alcaro is full professor of Medicinal Chemistry affiliated at the Dipartimento di Scienze della Salute, Università Magna Graecia di Catanzaro (Italy). He uses innovative computational techniques in rational drug discovery projects against anticancer targets (PTPRJ, DNA duplex and G-quadruplex) and other enzymes (HIV-1 RT, COX 1/2 and MAO A/B). He is co-author of about 110 publications.
  
  

• Glycofullerenes for Biological Applications
  Dr. Nazario MARTÍN LEÓN
  (UNIVERSIDAD COMPLUTENSE DE MADRID, Madrid, Spain)

  Dr. Nazario Martín is full professor at the UCM. His research interests span a range of targets with emphasis on the chemistry of fullerenes, carbon nanotubes, graphenes, π-conjugated systems as molecular wires, and electroactive molecules. He has been the recipient of the “Dupont Prize of Science” in 2007, the “Gold Medal and Research Award” by the Spanish Royal Society of Chemistry in 2012, the national “Jaime I Award for basic research” 2012, the “EuCheMS Lecture Award” in 2012, and more recently the “Alexander von Humboldt Award” .
  
  

• ORL-1 Antagonists: Lead Optimization and PET Tracer Development
  Dr. Angeles MARTÍNEZ GRAU
  (LILLY, S.A., Madrid, Spain)

  Dr. María Angeles Martínez Grau. Senior Research Advisor at Eli Lilly. PhD in Organic Chemistry by the UCM, she recieved the National Prize for Young Scientists (1995). After a postdoctoral stay at University of Pittsburgh, she joined Lilly in 1998. She has held different positions in the company, both in Madrid and Indianapolis, and has contributed to the delivery of 8 clinical candidates in the areas of Neuroscience, Obesity and Diabetes. She currently leads a group of 11 Medicinal Chemistry scientists working in Diabetes projects.
  
  

• Synthetic biology and smart therapeutic systems
  Dr. Guillermo de la CUEVA
  (BIONAD- Centro Andaluz de Nanomedicina y Biotecnología, Málaga, Spain)

  Dr. Guillermo de la Cueva Méndez is currently responsible and group leader of the Area of Therapeutic Nanosystems at the Centro Andaluz de Nanomedicina y Biotecnología (BIONAND). His research group is focused on the development of intelligent biological drugs and therapeutic nanosystems by means of Synthetic Biology. He graduated in Biochemistry and Molecular Biology at the UAM and obtained the PhD at CIB-CSIC. After a postdoctoral stay at the Wellcome/Cancer Research Campaign Institute (Cambridge, UK), he joined the Hutchison/MRC Research Centre (Cambridge, UK) as Principal Investigator, until his recent incorporation to BIONAD.
  
  

• Next-Generation Inhibitors for Kinases, Histone-Deacetylases, and Histone Methyltransferases: The discovery of Slowness
  Dr. Gerhard MÜLLER
  (MERCACHEM, The Netherlands)

  Dr. Gerhard Müller is Senior Vice President Medicinal Chemistry at Mercachem. PhD in Organic Chemistry by the Technical University of Munich, he has worked in different pharmaceutical companies, and on a wide range of target classes from numerous disease areas, always emphasizing target family-centric medicinal chemistry approaches. Over the last 10 years he specialized in kinase inhibitor research establishing novel design paradigms, proven by numerous publications.
  
  

• Antibiotic Treatment of Tuberculosis: Old Problems, New Solutions
  Dr. Mónica CACHO IZQUIERDO
  (GLAXOSMITHKLINE, Madrid, Spain)

  Dr. Mónica Cacho Izquierdo is Principal Scientist at TB DPU, Tres Cantos Medicines Development Center, GlaxoSmithKline. PhD in Organic Chemistry by the Universidad of San Pablo CEU (USP-CEU). After a post-doctoral stay at the University of Nottingham, she joined the USP-CEU as Profesor Colaborador. Later she moved to Noscira S.A., then to the Instituto de Química Médica (CSIC) and finally to GSK. Her research work covers several diseases (cancer, AIDS, Alzheimer) and targets (DNA topoisomerase, CDK-1, adrenomomedullin, reverse transcriptase). Currently her work is focused on the discovery of new anti-tuberculars.
  
  

• ETP-CNIO Academic Early Drug Discovery: PIM Kinase Inhibitors
  Dr. Joaquín PASTOR
  (CNIO- Centro Nacional de Investigaciones Oncológicas, Madrid, Spain)

  Dr. Joaquín Pastor, Ph.D. in Chemistry by the University of Alcalá de Henares (UAH). Postdoctoral stage (1994-1998) at The Scripps Research Institute (Prof. K.C. Nicolaou group). Back in Spain, he joined Janssen (J&J PRD) as head of the HTMC group and acting as team leader in different projects/therapeutic areas such as CNS, metabolic disorders and oncology, collaborating in the progression of compounds to NME stage. In 2008 he joined CNIO, and since 2011 he is Director of the Programme leading the drug discovery activities of the CNIO. He is author and co-author of more than 70 scientific publications and patents in the field of drug discovery.
  
  

• The asymmetric architecture of G protein-coupled receptor heteromers with G proteins explains signalling cross-talk
  Dr. Peter J. McCORMICK
  (UNIVERSITY OF BARCELONA, Barcelona, Spain)

  Dr. Peter J. McCormick. Bachelors in Science from Washington University in St. Louis. PhD in Biochemistry from Texas A&M University followed by postdoctoral research at the National Institutes of Health in Bethesda, Maryland, USA. He obtained a Ramon y Cajal in 2009 and moved to the University of Barcelona where he is a group leader in the Molecular Neurobiology group. His work involves the identification and understanding of G-protein coupled receptor heterodimers.
  
  

• Exploring the kinome with kinase broad screening
  Dr. Gary TRESADERN
  (JANSSEN R&D, Beerse, Belgium)

  Dr. Gary Tresadern currently heads the Molecular Informatics (MI) group at Janssen R&D in Belgium . Gary joined Janssen in 2005 as a computational chemist and molecular modeller and has contributed to multiple discovery projects reaching clinical evaluation. He has a particular interest in hit and lead generation, GPCRs, Kinases, and virtual screening. He graduated with a PhD in computational chemistry from the University of Manchester in 2003 and worked in the UK for Tripos Discovery Research from 2002 to 2005. He is co-author of 24 scientific articles, 2 book-chapters and co-inventor on 13 published patent applications.

INTERNATIONAL KINANTHROPOMETRY CERTIFICATION COURSE - ISAK LEVEL I

Kineanthropometry is the area of science concerned with the measurement of human body composition. Changes in lifestyles, nutrition, physical activity levels and ethnic composition of populations lead to changes in body dimensions. By measuring the human body and determining its capacity for function and movement in a wide range of areas, kinanthropometry is the link between anatomy and movement.

Course aimed at:

Students and Professionals in: Human Nutrition and Dietetics; Physical Activity and Sport Sciences, Medicine, Phisiotherapy, Nuirsing; Anthropology, Ergonomics, etc.

Objectives

• To know the history, evolution, and development of kinanthropometry at national and international level.
• To know the different applications of kinanthropometry.
• To master the technique of measuring the different anthropometric variables with the restricted profile (level 1).
• To train anthropometrists who work with quality, precision and in a standardised manner.

Content

• Theoretical
  
  • History of ISAK. ISAK International Accreditation Scheme.
  • Body's composition.
  • Proxemia and Ethics.
  • Instruments: handling and calibration of the equipment.
  • Anthropometric points restricted profile (level 1)
  • Take anthropometric measurements of the restricted profile (level 1)
  • Technical measurement error.
• Practical
  
  • Handling of anthropometric equipment (skinfold caliper, anthropometric tape and pachymeter).
  • Marking of anthropometric reference points of the restricted profile. 
  • Methodology for taking measurements. 

Evaluation

At the end of the course, candidates must pass a practical and theoretical exam, where they demonstrate their level of knowledge, precision and accuracy.

Upon completion of the course, candidates must complete 20 anthropometric profiles (measuring 20 people) and submit the results to the course director within 4 months of completing the course. If the accuracy is satisfactory, they will be awarded ISAK Certification, valid for 4 years and 4 months.

Requirements for ISAK certification

• 100% attendance at the course.
• Pass with a minimum grade of 80 % in the two theoretical and practical exams to be held on the last day of the course. The results of this assessment will be given on the day of the exam.
• Complete the measurement of 20 complete anthropometric profiles within the established deadlines (level 1: 4 months; level 2: 6 months) from the end of the course.

Director of the course

Dr. Ángela García González
Associate Professor, Department of Pharmaceutical and Health Sciences (Universidad CEU-San Pablo). Anthropometrist level 3-ISAK, Member of the Spanish Group in Cineanthropometry.

Faculty

• Dr. Natalia Úbeda Martín. Natalia Úbeda Martín. Full Professor of the Department of Pharmaceutical and Health Sciences (Universidad CEU-San Pablo). Anthropometrist level 2-ISAK. 
• Dr. Teresa Partearroyo Cediel. Collaborating Professor Doctor Department of Pharmaceutical and Health Sciences (Universidad CEU-San Pablo). Antropometrista nivel 2-ISAK.

Meeting place

• School of Pharmacy, Universidad CEU-San Pablo-Madrid
  Urb Montepríncipe, Av Montepríncipe s/n 28925 Alcorcón
  28925 Alcorcón Madrid, Spain.
  Telf. 91.372.47.00
• School of Pharmacy, Universidad CEU-San Pablo-Madrid
  Urb Montepríncipe, Av Montepríncipe s/n 28925 Alcorcón
  28925 Alcorcón Madrid, Spain.
  Telf. 91.372.47.00
• Buses
  571, 573, 574
• Light rail
  L3 (Montepríncipe)